期刊文献+

肌层浸润性膀胱癌患者根治性膀胱切除术的预后分析 被引量:22

Prognosis analysis of radical cystectomy in patients with muscle-invasive bladder cancer
下载PDF
导出
摘要 目的 探讨肌层浸润性膀胱癌患者根治性膀胱切除术的预后影响因素.方法 选择北京协和医院2008年1月至201 1年6月所收治的肌层浸润性尿路上皮细胞癌患者36例,采用Kaplan-Meier法以及Cox比例回归风险模型对预后影响因素包括患者的性别、年龄、TNM临床分期、术前是否行新辅助化疗、肿瘤数目、肿瘤大小、术后3个月卡氏评分、碱性磷酸酶、乳酸脱氢酶、血红蛋白等因素进行分析.结果 36例患者1年生存率为86.1% (31/36),3年生存率为75.0% (27/36).单因素分析发现,术前行新辅助化疗和术后卡氏评分是对根治性膀胱切除术预后有影响的因素(x2=8.532,P=0.003;x2=5.482,P=0.003).Cox比例回归风险模型分析提示术前行新辅助化疗是影响预后的独立因素(P=0.037,相对危险度0.107,95%置信区间:0.013 ~0.873).结论 根治性膀胱切除术的预后与患者术前行新辅助化疗有关,样前行新辅助化疗为保护因子. Objective To explore the prognosis factors of radical cystectomy in patients with muscleinvasive bladder cancer factors of radical bladder cystectomy.Methods Clinical data of 36 cases with muscleinvasive bladder cancer after radical cystectomy from January 2008 to June 2011 were selected.Kapplan-Meier method and Cox regression model were used to analyze the prognosis factors including sex,age,hematuria,clinical staging,neoadjavant chemotherapy,tumor number,tumor size,Kamofsky scores 3 months after operation,alkaline phosphatase,lactic dehydrogenase and hemoglobin..Results The 1 year and 3 years survival rates were 86.1% (31/36) and 75% (27/36),respectively.Kaplan-Meier method showed that preoperative neoadjavant chemotherapy and postoperative Karnofsky scores were the influencing factors of prognosis (x2 =8.532,P =0.003 ; x2 =5.482,P =0.003).Cox regression model showed that preoperative neoadjuvant chemotherapy was the independent factor of prognosis (P =0.037,RR =0.107,95% CI:0.013-0.873).Conclusion There is a correlation between prognosis of radical cystectomy and preoperative neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer; preoperative neoajuvant chemotherapy is the protective factor.
出处 《中国医药》 2015年第9期1344-1346,共3页 China Medicine
关键词 肌层浸润性膀胱癌 膀胱癌根治术 预后因素 Muscle-invasive bladder cancer Cystectomy Prognostic factor
  • 相关文献

参考文献3

二级参考文献20

  • 1Dr. F. Dorp,C. B?rgermann,A. Rose,M. Becker,H. Rübben.Targeted-Therapie des metastasierten Urothelkarzinoms[J]. Der Urologe . 2008 (10)
  • 2Ono M,Hirata A,Kometani T.Sensitivity to gefitinib (Ires-sa,ZD1839)in non-small cell lung cancer cell lines corre-lates with dependence on the epidermal growth factor (EGF)receptor/extracellular signal-regulated kinase 1/2and EGF receptor/Akt pathway for proliferation. MolCancer Ther . 2004
  • 3Silay MS,Miroglu C.Sunitinib malate and sorafenib maybe beneficial at the treatment of advanced bladder cancerdue to their anti-angiogenic effects. Medical Hypotheses . 2007
  • 4Beekman KW,Bradley D,Hussain M.New molecular tar-gets and novel agents in the treatment of advanced urothelialcancer. Seminars in Oncology . 2007
  • 5Landis SH,Murray T,Bolden S,et al.Cancer statistics, 1999. CA A Cancer Journal for Clinicians . 1999
  • 6Froehner M,Hakenberg OW,Wirth MP.Molecular therapy in urologic oncology. Urologia Internationalis . 2007
  • 7Silay MS,Miroglu C. Sunitinib malate and sorafenib may be beneficial at the treatment of advanced bladder cancer due to their anti-angiogenic effects[J].Medical Hypotheses,2007,(04):892-895.doi:10.1016/j.mehy.2007.01.065.
  • 8Landis SH,Murray T,Bolden S. Cancer statistics,1999[J].CA:A Cancer Journal for Clinicians,1999,(01):8-31.doi:10.3322/canjclin.49.1.8.
  • 9Vom Dorp F,B(o)rgermann C,Rose A. Targeted therapy for metastatic bladder cancer[J].Urologe Ausgabe A,2008,(10):1311-1314.
  • 10Ono M,Hirata A,Kometani T. Sensitivity to gefitinib (Iressa,ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF)receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation[J].Molecular Cancer Therapeutics,2004,(04):465-472.

共引文献5

同被引文献190

  • 1荣誉,张锦英.根治性经尿道膀胱肿瘤电切术治疗老年肌层浸润性膀胱癌的疗效及对生活质量的影响[J].中国老年学杂志,2014,34(12):3351-3353. 被引量:42
  • 2陈江辉,刘瑶,郭曲练.乌司他丁对颅脑手术患者血清白细胞介素-6和肿瘤坏死因子α的影响[J].临床麻醉学杂志,2004,20(10):585-586. 被引量:6
  • 3万崇华,孟琼,汤学良,张灿珍,罗家洪,张晓磐.癌症患者生命质量测定量表FACT-G中文版评介[J].实用肿瘤杂志,2006,21(1):77-80. 被引量:400
  • 4Jaime L,Kurt K,Jmil R,et al.Eveluation of a vessel sealing system,ipolar electrosurgery,harmonic scalpel,titanium clip,endoscopic gastrointestinal anastomosis vascular staples and sutures for arterial and venous ligation in a porcine model[J].J Urol,2013,2(11):697-700.
  • 5Moynihan C,Lewis R,Hall E,et al.The patient deficit model overturned:A qualitative study of patients' perceptions of invitation to participate in a randomized controlled trial comparing selective bladder preservation against surgery in muscle invasive bladder cancer[J].Trials,2012,29(13):228.
  • 6Yüksel H,Verit A,rkmez A.What is the correct staging and treatment strategy for locally advanced prostate cancer extending to the bladder[J]-Arch Ital Urol Androl,2015,87(2):130-135.
  • 7Hadjiiski L,Weizer AZ,Alva A,et al.Treatment response assessment for bladder cancer on CT based on computerized volume analysis,World Health Organization criteria,and RECIST[J].AJR Am J Roentgenol,2015,205(2):348-352.
  • 8Ramos M,Franch P,Zaforteza M,et al.Completeness of T,N,M and stage grouping for all cancers in the Mallorca Cancer Registry[J].BMC Cancer,2015,4(15):847-849.
  • 9Allard CB,Meyer CP,Gandaglia G,et al.The effect of resident involvement on perioperative outcomes in transurethral urologic surgeries[J].J Surg Educ,2015,4(15):100-102.
  • 10Tolkach Y,Godin K,Petrov S,et al.A new technique of bladder neck reconstruction during radical prostatectomy in patients with prostate cancer[J].Int Braz J Urol,2015,41(3):455-465.

引证文献22

二级引证文献100

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部